Advantages and Opportunities

Dyadic International, Inc. (NASDAQ: DYAI)

We are a global biotechnology company committed to building disruptive microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products for human and animal health.

With a passion to enable our partners and collaborators to develop effective preventative and therapeutic treatments in both developed and emerging countries, Dyadic is building an active pipeline by advancing its proprietary filamentous fungal based


  • Stable Cell lines in ~7 weeks
  • Research Cell Bank becomes Master Cell Bank
  • No viral or endotoxin inactivation
  • 3-7 day fermentation (continuous in development)


  • Up to 300 times more productive than certain currently used vaccine cell lines
  • Up to 10 times more productive than certain currently used mammalian cell lines
  • Industrially proven platform that has run at up to 500,000L
  • Record levels of 10g/L of an antigen, >22 g/L of a monoclonal antibody


  • Industrial scale flexibility and scale
  • C1 can lower CAPEX:
    • Produce at smaller scale while dramatically increasing protein yields
    • Unparallelled productivity provides margin relief
  • C1 can lower OPEX
    • Smaller facility footprint and related costs
    • Industrial media costs for pharma grade materials